drugset / Trial / NCT01977378

A Study of Sustained-Release Desvenlafaxine Hydrochloride for the Treatment of Major Depressive Disorder

NCT01977378

Phase 2/3 Unknown 300 enrolled Jiangsu Hansoh Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

A multicenter, 10-week study to evaluate the efficacy and safety of Sustained-Release Desvenlafaxine Hydrochloride versus Sustained-Release venlafaxine Hydrochloride in adult with major depressive disorder.

Timeline

Start
2013-10
Primary completion
2014-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Desvenlafaxine Other / unclassified 50 mg
Subject Desvenlafaxine Other / unclassified 100 mg
Comparator Venlafaxine Small molecule 75 mg
Comparator Venlafaxine Small molecule 225 mg